BioNxt Solutions Inc. has announced the expansion and protection of its proprietary drug delivery platform focusing on neurological autoimmune disorders. The company has begun the examination process for its U.S. patent application for BNT23001, a novel sublingual thin-film cladribine formulation for multiple sclerosis (MS), under the United States Patent and Trademark Office's (USPTO) Track One Program.
BioNxt has also received the approval of core claims for a broad international patent designed as a platform-level umbrella protecting the Company's sublingual thin-film delivery technology across a broad range of diseases, drug compounds, as well as applications.
Fast-Tracked U.S. Patent Filing via Track One to Accelerate Clinical Development Milestones
In order to stimulate patent review for BNT23001, BioNxt is working with the USPTO's Track One Prioritized Examination Program. If accepted, this program will set a final patent disposition within 12 months, with most applicants receiving a first Office Action in approximately two months and a final decision in under seven months. For BioNxt, this fast-tracks status represents a strategic move to secure near-term U.S. patent protection as well as strengthen its IP position ahead of pivotal bioequivalence studies and commercial partnering discussions.
BioNxt's Broad Patent: A Platform-Level Umbrella for Autoimmune Neurology:
The umbrella patent will enable long-term exclusivity, extending into the 2040s, not only for cladribine, but for a broad class of drug compounds delivered via BioNxt's proprietary sublingual thin-film technology. This includes protection for composition, manufacturing, administration methods, as well as use across multiple autoimmune and neuroinflammatory indications.
Significant Unmet Need
Autoimmune neurodegenerative diseases has limited therapeutic options with poor adherence to existing therapies. BioNxt's thin-film delivery technology is manufactured to enhance tolerability along with usability across these patient populations. BioNxt's thin-film platform bypasses the gastrointestinal tract, helps rapid absorption, as well as improves dosing convenience, critical in chronic autoimmune disorders where long-term care is essential.